GFM
QTTB icon

GF Fund Management’s Q32 Bio QTTB Stock Holding History

GF Fund Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-227
Closed -$449 – 702
2025
Q3 		$449 Sell
227
-37
-14% -$71 ﹤0.01% 631
2025
Q2 		$393 Hold
264
– – ﹤0.01% 660
2025
Q1 		$436 Buy
264
+8
+3% +$22 ﹤0.01% 665
2024
Q4 		$881 Buy
+256
New +$8.08K ﹤0.01% 637

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GF Fund Management's QTTB Position: Q4 2025 in Review

GF Fund Management sold out of Q32 Bio (QTTB) in Q4 2025, closing a stake of 227 shares — an estimated $449 sold.

GF Fund Management first reported a position in QTTB in Q4 2024 and held it in 4 quarters. The position peaked at $881 in Q4 2024. 52 funds tracked by Wall St. Rank hold QTTB as of Q4 2025.

  • GF Fund Management reported no remaining Q32 Bio position as of Q4 2025 after selling out during the quarter.
  • GF Fund Management sold 227 Q32 Bio shares in Q4 2025, an estimated $449.
  • GF Fund Management first reported a position in Q32 Bio in Q4 2024 and held it in 4 quarters.
  • GF Fund Management's Q32 Bio position peaked at $881 in Q4 2024.
  • 52 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2025.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.